Multicenter retrospective study on the use of Curebest™ 95GC Breast for estrogen receptor-positive and node-negative early breast cancer

A 95-gene signature stratifies recurrence risk of invasive disease in ER-positive, HER2-negative, node-negative breast cancer with intermediate 21-gene signature recurrence scores

(2021) Takeo Fujii et al.   BREAST CANCER RESEARCH AND TREATMENT

Risk of loco-regional recurrence and distant metastases of patients with invasive breast cancer up to ten years after diagnosis – results from a registry-based study from Germany

(2019) Bernd Holleczek et al.   BMC CANCER

Development of recurrence risk score using 95‑gene classifier and its application to formalin‑fixed paraffin‑embedded tissues in ER‑positive, HER2‑negative and node‑negative breast cancer

(2019) Yasuto Naoi et al.   ONCOLOGY REPORTS

Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial

(2018) Irene L. Wapnir et al.   JOURNAL OF CLINICAL ONCOLOGY

Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries

(2018) Claudia Allemani et al.   LANCET

Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer

(2018) Joseph A. Sparano et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comparing Breast Cancer Multiparameter Tests in the OPTIMA Prelim Trial: No Test Is More Equal Than the Others

(2016) John M. S. Bartlett et al.   JNCI-Journal of the National Cancer Institute

Comparing Breast Cancer Multiparameter Tests in the OPTIMA Prelim Trial: No Test Is More Equal Than the Others

(2016) John M. S. Bartlett et al.   JNCI-Journal of the National Cancer Institute

Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone

(2013) M. Gnant et al.   ANNALS OF ONCOLOGY

Comparison of efficacy of 95-gene and 21-gene classifier (Oncotype DX) for prediction of recurrence in ER-positive and node-negative breast cancer patients

(2013) Yasuto Naoi et al.   BREAST CANCER RESEARCH AND TREATMENT

The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysis

(2013) Josh J. Carlson et al.   BREAST CANCER RESEARCH AND TREATMENT

Estrogen receptor positive breast cancer identified by 95-gene classifier as at high risk for relapse shows better response to neoadjuvant chemotherapy

(2012) Ryo Tsunashima et al.   CANCER LETTERS

Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry

(2011) Seho Park et al.   BREAST

Development of 95-gene classifier as a powerful predictor of recurrences in node-negative and ER-positive breast cancer patients

(2010) Yasuto Naoi et al.   BREAST CANCER RESEARCH AND TREATMENT

A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor-Positive Breast Cancer

(2010) T. O. Nielsen et al.   CLINICAL CANCER RESEARCH

Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes

(2009) Joel S. Parker et al.   JOURNAL OF CLINICAL ONCOLOGY